Skip to main content
Top
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology 2/2011

01-02-2011 | Medical Ophthalmology

Focal macular electroretinograms after photodynamic therapy combined with intravitreal bevacizumab

Authors: Kohei Ishikawa, Hiroaki Nishihara, Shinsuke Ozawa, Chang-Hua Piao, Yasuki Ito, Mineo Kondo, Hiroko Terasaki

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 2/2011

Login to get access

Abstract

Background

Retinal function is transiently depressed after photodynamic therapy (PDT) alone. One of the reasons for this functional impairment is a reduction of choroidal circulation caused by the PDT. The purpose of this study was to determine whether PDT combined with intravitreal bevacizumab (PDT+IVB) can reduce or prevent the transient impaired macular function. In addition, we examined whether a significant correlation existed between the changes in the focal macular electroretinograms (FMERGs), optical coherence tomography (OCT)-determined morphology, and changes in choroidal circulation.

Methods

Thirty-eight eyes that were treated by full fluence PDT+IVB were studied. FMERGs, OCT, and indocyanine green angiography (ICGA) were performed before and after the PDT. The intensity of the diffuse fluorescence within the PDT site was measured by densitometry (I/N ratio).

Results

The macula was significantly thinner 1 week after PDT+IVB (P < 0.01). The mean a- and b-wave amplitudes of the FMERGs were not significantly decreased 1 week after PDT+IVB. The mean b-wave amplitudes 3 months after PDT+IVB were significantly increased (P < 0.01). The I/N ratio of ICGA 3 months after PDT+IVB was 0.88 ± 0.1. The correlation between the FMERGs and I/N ratio was not significant.

Conclusion

The use of IVB with PDT mitigates the reduction of the FMERGs and reduces the macular thickness soon after PDT, regardless of the degree of impairment of choroidal circulation caused by PDT. Finally, the macular retinal function 3 months after PDT+IVB were better than that before the treatment.
Literature
1.
go back to reference Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report 1. Arch Ophthalmol 117:1329–1345 Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report 1. Arch Ophthalmol 117:1329–1345
2.
go back to reference Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of two randomized clinical trials-TAP report 2. Arch Ophthalmol 119:198–207 Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of two randomized clinical trials-TAP report 2. Arch Ophthalmol 119:198–207
3.
go back to reference Verteporfin in Photodynamic Therapy Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial. VIP report 1. Ophthalmology 108:841–852CrossRef Verteporfin in Photodynamic Therapy Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial. VIP report 1. Ophthalmology 108:841–852CrossRef
4.
go back to reference Verteporfin in Photodynamic Therapy Study Group (2001) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization: verteporfin in photodynamic therapy report 2. Am J Ophthalmol 131:541–560CrossRef Verteporfin in Photodynamic Therapy Study Group (2001) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization: verteporfin in photodynamic therapy report 2. Am J Ophthalmol 131:541–560CrossRef
5.
go back to reference Japanese Age-Related Macular Degeneration Trial (JAT) Study Group (2003) Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol 136:1049–1061CrossRef Japanese Age-Related Macular Degeneration Trial (JAT) Study Group (2003) Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol 136:1049–1061CrossRef
6.
go back to reference Verteporfin Roundtable Participants (2005) Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina 25:119–134CrossRef Verteporfin Roundtable Participants (2005) Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina 25:119–134CrossRef
7.
go back to reference Moschos MN, Panayotidis D, Moschos MM, Bouros C, Theodossiadis PG, Theodossiadis GP (2003) A preliminary assessment of macular function by MF-ERG in myopic eyes with CNV with complete response to photodynamic therapy. Eur J Ophthalmol 13:461–467PubMed Moschos MN, Panayotidis D, Moschos MM, Bouros C, Theodossiadis PG, Theodossiadis GP (2003) A preliminary assessment of macular function by MF-ERG in myopic eyes with CNV with complete response to photodynamic therapy. Eur J Ophthalmol 13:461–467PubMed
8.
go back to reference Rüther K, Breidenbach K, Schwartz R, Hassenstein A, Richard G (2003) Testing central retinal function with multifocal electroretinography before and after photodynamic therapy. Ophthalmologe 100:459–464PubMed Rüther K, Breidenbach K, Schwartz R, Hassenstein A, Richard G (2003) Testing central retinal function with multifocal electroretinography before and after photodynamic therapy. Ophthalmologe 100:459–464PubMed
9.
go back to reference Lai TY, Chan WM, Lam DS (2004) Transient reduction in retinal function revealed by multifocal electroretinogram after photodynamic therapy. Am J Ophthalmol 137:826–833CrossRefPubMed Lai TY, Chan WM, Lam DS (2004) Transient reduction in retinal function revealed by multifocal electroretinogram after photodynamic therapy. Am J Ophthalmol 137:826–833CrossRefPubMed
10.
go back to reference Ishikawa K, Kondo M, Ito Y, Kikuchi M, Nishihara H, Piao CH, Sugita T, Terasaki H (2007) Correlation between focal macular electroretinograms and angiographic findings after photodynamic therapy. Investig Ophthalmol Vis Sci 48:2254–2259CrossRef Ishikawa K, Kondo M, Ito Y, Kikuchi M, Nishihara H, Piao CH, Sugita T, Terasaki H (2007) Correlation between focal macular electroretinograms and angiographic findings after photodynamic therapy. Investig Ophthalmol Vis Sci 48:2254–2259CrossRef
11.
go back to reference Van de Moere A, Sandhu SS, Kak R, Mitchell KW, Talks SJ (2005) Effect of posterior juxtascleral triamcinolone acetonide on choroidal neovascular growth after photodynamic therapy with verteporfin. Ophthalmology 112:1896–1903CrossRefPubMed Van de Moere A, Sandhu SS, Kak R, Mitchell KW, Talks SJ (2005) Effect of posterior juxtascleral triamcinolone acetonide on choroidal neovascular growth after photodynamic therapy with verteporfin. Ophthalmology 112:1896–1903CrossRefPubMed
12.
go back to reference Spaide RF, Sorenson J, Maranan L (2003) Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 110:1517–1525CrossRefPubMed Spaide RF, Sorenson J, Maranan L (2003) Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 110:1517–1525CrossRefPubMed
13.
go back to reference Spaide RF, Sorenson J, Maranan L (2005) Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 112:301–304CrossRefPubMed Spaide RF, Sorenson J, Maranan L (2005) Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 112:301–304CrossRefPubMed
14.
go back to reference Rechtman E, Danis RP, Pratt LM, Harris A (2004) Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularization in age related macular degeneration. Br J Ophthalmol 88:344–347CrossRefPubMed Rechtman E, Danis RP, Pratt LM, Harris A (2004) Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularization in age related macular degeneration. Br J Ophthalmol 88:344–347CrossRefPubMed
15.
go back to reference Chan WM, Lai TY, Wong AL, Tong JP, Liu DT, Lam DS (2006) Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularization in age related macular degeneration. A comparative study. Br J Ophthalmol 90:337–341CrossRefPubMed Chan WM, Lai TY, Wong AL, Tong JP, Liu DT, Lam DS (2006) Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularization in age related macular degeneration. A comparative study. Br J Ophthalmol 90:337–341CrossRefPubMed
16.
go back to reference Krebs I, Binder S, Stolba U (2006) A new treatment regimen in combined intravitreal injection of triamcinolone acetonide and photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 244:863–867CrossRefPubMed Krebs I, Binder S, Stolba U (2006) A new treatment regimen in combined intravitreal injection of triamcinolone acetonide and photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 244:863–867CrossRefPubMed
17.
go back to reference Nicolò M, Ghiglione D, Lai S, Nasciuti F, Cicinelli S, Calabria G (2006) Occult with no classic choroidal neovascularization secondary to age related macular degeneration treated by intravitreal triamcinolone and photodynamic therapy with verteporfin. Retina 26:58–64CrossRefPubMed Nicolò M, Ghiglione D, Lai S, Nasciuti F, Cicinelli S, Calabria G (2006) Occult with no classic choroidal neovascularization secondary to age related macular degeneration treated by intravitreal triamcinolone and photodynamic therapy with verteporfin. Retina 26:58–64CrossRefPubMed
18.
go back to reference Augustin AJ, Schmidt-Erfurth U (2006) Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age related macular degeneration. Ophthalmology 113:14–22CrossRefPubMed Augustin AJ, Schmidt-Erfurth U (2006) Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age related macular degeneration. Ophthalmology 113:14–22CrossRefPubMed
19.
go back to reference Ruiz-Moreno JM, Montero J, Barile S, Zarbin M (2006) Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 1-year outcome. Retina 26:602–612CrossRefPubMed Ruiz-Moreno JM, Montero J, Barile S, Zarbin M (2006) Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 1-year outcome. Retina 26:602–612CrossRefPubMed
20.
go back to reference Ruiz-Moreno JM, Montero J, Barile S (2006) Triamcinolone and PDT to treat exudative age-related macular degeneration and submacular hemorrhage. Eur J Ophthalmol 16:426–434PubMed Ruiz-Moreno JM, Montero J, Barile S (2006) Triamcinolone and PDT to treat exudative age-related macular degeneration and submacular hemorrhage. Eur J Ophthalmol 16:426–434PubMed
21.
go back to reference Augustin AJ, Schmidt-Erfurth U (2006) Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age related macular degeneration. Am J Ophthalmol 141:638–645CrossRefPubMed Augustin AJ, Schmidt-Erfurth U (2006) Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age related macular degeneration. Am J Ophthalmol 141:638–645CrossRefPubMed
22.
go back to reference Ishikawa K, Nishihara H, Ozawa S, Piao CH, Ito Y, Kondo M, Terasaki H (2009) Focal macular electroretinograms after photodynamic therapy combined with posterior juxtascleral triamcinolone acetonide. Retina 29:803–810CrossRefPubMed Ishikawa K, Nishihara H, Ozawa S, Piao CH, Ito Y, Kondo M, Terasaki H (2009) Focal macular electroretinograms after photodynamic therapy combined with posterior juxtascleral triamcinolone acetonide. Retina 29:803–810CrossRefPubMed
23.
go back to reference Schmidt-Erfurth U, Schlötzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO (2003) Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Investig Ophthalmol Vis Sci 44:4473–4480CrossRef Schmidt-Erfurth U, Schlötzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO (2003) Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Investig Ophthalmol Vis Sci 44:4473–4480CrossRef
24.
go back to reference Jorge R, Costa RA, Calucci D, Scott IU (2007) Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Graefes Arch Clin Exp Ophthalmol 245:1273–1280CrossRefPubMed Jorge R, Costa RA, Calucci D, Scott IU (2007) Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Graefes Arch Clin Exp Ophthalmol 245:1273–1280CrossRefPubMed
25.
go back to reference Smith BT, Dhalla MS, Shah GK, Blinder KJ, Ryan EH Jr, Mittra RA (2008) Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in aged-related macular degeneration. Retina 28:675–681CrossRefPubMed Smith BT, Dhalla MS, Shah GK, Blinder KJ, Ryan EH Jr, Mittra RA (2008) Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in aged-related macular degeneration. Retina 28:675–681CrossRefPubMed
26.
go back to reference Weigert G, Michels S, Sacu S, Varga A, Prager F, Geitzenauer W, Schmidt-Erfurth U (2008) Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomized, controlled clinical study. Br J Ophthalmol 92:356–360CrossRefPubMed Weigert G, Michels S, Sacu S, Varga A, Prager F, Geitzenauer W, Schmidt-Erfurth U (2008) Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomized, controlled clinical study. Br J Ophthalmol 92:356–360CrossRefPubMed
27.
go back to reference Ladewig MS, Karl SE, Hamelmann V, Helb HM, Scholl HP, Holz FG, Eter N (2008) Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 246:17–25CrossRefPubMed Ladewig MS, Karl SE, Hamelmann V, Helb HM, Scholl HP, Holz FG, Eter N (2008) Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 246:17–25CrossRefPubMed
28.
go back to reference Zuo C, Wen F, Li J, Liu Y, Li M (2009) Transitions of multifocal electroretinography following combined intravitreal bevacizumab and photodynamic therapy for polypoidal choroidal vasculopathy. Doc Ophthalmol 119:29–36CrossRefPubMed Zuo C, Wen F, Li J, Liu Y, Li M (2009) Transitions of multifocal electroretinography following combined intravitreal bevacizumab and photodynamic therapy for polypoidal choroidal vasculopathy. Doc Ophthalmol 119:29–36CrossRefPubMed
29.
go back to reference Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363–372CrossRefPubMed Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363–372CrossRefPubMed
30.
go back to reference Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26:383–390CrossRefPubMed Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26:383–390CrossRefPubMed
31.
go back to reference Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LA Jr, Scott IU (2006) Intravitreal bevacizumab (Avastin) for choroidal neovascularization caused by age-related macular degeneration (IBeNA Study): results of a dose-escalation study. Investig Ophthalmol Vis Sci 47:4569–4578CrossRef Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LA Jr, Scott IU (2006) Intravitreal bevacizumab (Avastin) for choroidal neovascularization caused by age-related macular degeneration (IBeNA Study): results of a dose-escalation study. Investig Ophthalmol Vis Sci 47:4569–4578CrossRef
32.
go back to reference Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL, Sorenson J, Slakter JS, Freund KB, Cooney M, Fine HF (2006) Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 26:279–284CrossRefPubMed Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL, Sorenson J, Slakter JS, Freund KB, Cooney M, Fine HF (2006) Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 26:279–284CrossRefPubMed
33.
go back to reference Peters S, Heiduschka P, Julien S, Ziemssen F, Fietz H, Bartz-Schmidt KU, Tübingen Bevacizumab Study Group, Schraermeyer U (2007) Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 143:995–1002CrossRefPubMed Peters S, Heiduschka P, Julien S, Ziemssen F, Fietz H, Bartz-Schmidt KU, Tübingen Bevacizumab Study Group, Schraermeyer U (2007) Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 143:995–1002CrossRefPubMed
34.
go back to reference Miyake Y, Shiroyama N, Ota I, Horiguchi M (1988) Oscillatory potentials in electroretinograms of the human macular region. Investig Ophthalmol Vis Sci 29:1631–1635 Miyake Y, Shiroyama N, Ota I, Horiguchi M (1988) Oscillatory potentials in electroretinograms of the human macular region. Investig Ophthalmol Vis Sci 29:1631–1635
35.
go back to reference Miyake Y (1988) Studies of local macular ERG. Acta Soc Ophthalmol Jpn 92:1419–1449 Miyake Y (1988) Studies of local macular ERG. Acta Soc Ophthalmol Jpn 92:1419–1449
36.
go back to reference Ishikawa K, Ito Y, Mizutani R, Kikuchi M, Nishihara H, Terasaki H (2008) New computer program to analyze OCT images of fovea quantitatively before and after photodynamic therapy. Jpn J Ophthalmol 52:182–189CrossRefPubMed Ishikawa K, Ito Y, Mizutani R, Kikuchi M, Nishihara H, Terasaki H (2008) New computer program to analyze OCT images of fovea quantitatively before and after photodynamic therapy. Jpn J Ophthalmol 52:182–189CrossRefPubMed
37.
go back to reference Hatta Y, Ishikawa K, Nishihara H, Ozawa S, Ito Y, Terasaki H (2010) Effect of photodynamic therapy alone or combined with posterior subtenon triamcinolone acetonide or intravitreal bevacizumab on choroidal perfusion. Retina 30:495–502CrossRefPubMed Hatta Y, Ishikawa K, Nishihara H, Ozawa S, Ito Y, Terasaki H (2010) Effect of photodynamic therapy alone or combined with posterior subtenon triamcinolone acetonide or intravitreal bevacizumab on choroidal perfusion. Retina 30:495–502CrossRefPubMed
38.
go back to reference Obata R, Iriyama A, Inoue Y, Takahashi H, Tamaki Y, Yanagi Y (2007) Triamcinolone acetonide suppresses early proangiogenic response in RPE cells after photodynamic therapy in vitro. Br J Ophthalmol 91:100–104CrossRefPubMed Obata R, Iriyama A, Inoue Y, Takahashi H, Tamaki Y, Yanagi Y (2007) Triamcinolone acetonide suppresses early proangiogenic response in RPE cells after photodynamic therapy in vitro. Br J Ophthalmol 91:100–104CrossRefPubMed
Metadata
Title
Focal macular electroretinograms after photodynamic therapy combined with intravitreal bevacizumab
Authors
Kohei Ishikawa
Hiroaki Nishihara
Shinsuke Ozawa
Chang-Hua Piao
Yasuki Ito
Mineo Kondo
Hiroko Terasaki
Publication date
01-02-2011
Publisher
Springer-Verlag
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 2/2011
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-010-1548-x

Other articles of this Issue 2/2011

Graefe's Archive for Clinical and Experimental Ophthalmology 2/2011 Go to the issue